Compare Indonesia Energy Corporation Limited (INDO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Viatris Inc — how do they compare? Indonesia Energy Corporation Limited trades at $3.02 (market cap $46.01M), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 430.1× Indonesia Energy Corporation Limited's market cap, and Viatris Inc pays a 2.83% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | VTRS | |
|---|---|---|
Market Cap | $46.01M | $19.79B |
Sector | Energy | Health |
52-Week High | $6.74 | $17.39 |
52-Week Low | $2.49 | $8.74 |
Enterprise Value | $41.38M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical outlook supported by positive moving averages and ADX signals. The company is in a high-risk growth phase, reporting a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block, which could drive future revenue if successful.
The stock presents speculative upside tied to execution on new oil wells, but carries significant fundamental risk due to current losses and high valuation multiples. Analyst consensus is unanimously bullish, yet investors must weigh potential operational success against the company's fragile financial position and dependence on successful resource extraction.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
